ArticleBreast cancer research : BCR2026
Tumor heterogeneity index from DCE-MRI for AKT-inhibition responder identification and reveals hot immune microenvironment for patients with breast cancer: a multi-omics analysis of I-SPY2 trial.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Discrimination of Triple-Negative Breast Cancer: A Robust Clinical Baseline versus Multimodal Magnetic Resonance Imaging Integrated Models with Assessment of Generalizability.Breast cancer (Dove Medical Press) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundThe pan-AKT inhibitor MK2206 has shown improved but limited efficacy in achieving pathologic complete response (pCR) in patients with breast cancer receiving standard neoadjuvant chemotherapy (NACT). This study aimed to develop non-invasive tumor heterogeneity index (THI) from dynamic-contrast-enhanced magnetic resonance imaging (DCE-MRI) that can better select AKT-inhibition responders than immunohistochemistry (IHC)-based receptors and explore associated tumor microenvironment (TME). PATIENTS AND
methodsWe included 987 patients who underwent surgery following neoadjuvant chemotherapy (NACT) in the I-SPY2 trial, which comprised three cohorts: THI discovery, THI validation, and TME exploration. THI was constructed by regression on the consensus clustering labels using repeatable, reproducible, and specifically predictive radiomics-based features. The predictive value of THI for treatment outcomes was evaluated using AUC-ROC with cross-validation, while its clinical utility was assessed through Bayesian logistic regression. Additionally, we explored differentially expressed phosphoproteins, proteins, genes, biological mechanisms, and the tumor immune microenvironment.
resultsSeven repeatable image features were identified to be specifically predictive in the MK2206 arm and yielded two consensus clusters. The developed THI accurately predicted the two clusters, achieving an AUC-ROC of 1 in the discovery cohort and 0.99 in the remaining patients. It was significantly associated with treatment response in the AKT inhibition cohort with a cross-validation AUC of 0.73 (95% CI 0.63 to 0.83), and in corresponding subgroups (HER2−, HER2+, HR−) where AUCs ranged from 0.73 (95% CI 0.63 to 0.83) to 0.85 (95% CI 0.73 to 0.96). Bayesian analysis indicated that patients with high THI had a higher estimated average pCR rate of 56.1% in the AKT inhibition arm compared to 18.7% in the control arm (p < 0.001). Furthermore, high THI was associated with a "hot" tumor immune microenvironment, characterized by active immune pathways, extensive immune cell infiltration, and decreased cell cycle activity.
conclusionsThe Tumor Heterogeneity Index was found to be specifically and independently associated with the response to AKT inhibition, highlighting its potential to aid in responder prediction. Additionally, the associated tumor microenvironment enhances our understanding of the antitumor mechanisms underlying AKT inhibition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.